Preclinical studies showed that combining ruxolitinib with the CML-specific TKIs eliminated CD34+/CD38− stem cells with no effects on normal HSCs in-vitro, and reduced CD34+ cell engraftment to the BM in-vivo [131]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.